These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 30299591

  • 1. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and heart failure.
    Martinez BK, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI.
    ESC Heart Fail; 2019 Feb; 6(1):10-15. PubMed ID: 30299591
    [Abstract] [Full Text] [Related]

  • 2. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
    Coleman CI, Turpie AGG, Bunz TJ, Eriksson D, Sood NA, Baker WL.
    Eur Heart J Cardiovasc Pharmacother; 2019 Apr 01; 5(2):64-69. PubMed ID: 30020424
    [Abstract] [Full Text] [Related]

  • 3. Effectiveness and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and coronary or peripheral artery disease.
    Coleman CI, Baker WL, Meinecke AK, Eriksson D, Martinez BK, Bunz TJ, Alberts MJ.
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul 01; 6(3):159-166. PubMed ID: 31549153
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effectiveness and safety of rivaroxaban and warfarin for prevention of major adverse cardiovascular or limb events in patients with non-valvular atrial fibrillation and type 2 diabetes.
    Baker WL, Beyer-Westendorf J, Bunz TJ, Eriksson D, Meinecke AK, Sood NA, Coleman CI.
    Diabetes Obes Metab; 2019 Sep 01; 21(9):2107-2114. PubMed ID: 31099460
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Rivaroxaban vs. warfarin and renal outcomes in non-valvular atrial fibrillation patients with diabetes.
    Hernandez AV, Bradley G, Khan M, Fratoni A, Gasparini A, Roman YM, Bunz TJ, Eriksson D, Meinecke AK, Coleman CI.
    Eur Heart J Qual Care Clin Outcomes; 2020 Oct 01; 6(4):301-307. PubMed ID: 31432074
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
    Coleman CI, Peacock WF, Bunz TJ, Alberts MJ.
    Stroke; 2017 Aug 01; 48(8):2142-2149. PubMed ID: 28655814
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population.
    Gupta K, Trocio J, Keshishian A, Zhang Q, Dina O, Mardekian J, Rosenblatt L, Liu X, Hede S, Nadkarni A, Shank T.
    J Manag Care Spec Pharm; 2018 Nov 01; 24(11):1116-1127. PubMed ID: 30212268
    [Abstract] [Full Text] [Related]

  • 16. The effectiveness and safety of low-dose rivaroxaban in Asians with non-valvular atrial fibrillation.
    Lee HF, Chan YH, Tu HT, Kuo CT, Yeh YH, Chang SH, Wu LS, See LC.
    Int J Cardiol; 2018 Jun 15; 261():78-83. PubMed ID: 29559181
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, Shah ND, Noseworthy PA.
    J Am Heart Assoc; 2016 Jun 13; 5(6):. PubMed ID: 27412905
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Risk of Stroke Outcomes in Atrial Fibrillation Patients Treated with Rivaroxaban and Warfarin.
    Milentijevic D, Lin JH, Connolly N, Chen YW, Kogan E, Shrivastava S, Sjoeland E, Alberts MJ.
    J Stroke Cerebrovasc Dis; 2021 May 13; 30(5):105715. PubMed ID: 33743312
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.